<DOC>
	<DOCNO>NCT02653391</DOCNO>
	<brief_summary>This Phase 1/2 , prospective , randomize , double-masked , vehicle control , paired-eye study approximately 16 subject evaluate safety , tolerability efficacy elamipretide 1.0 % topical ophthalmic solution patient FCED present mild moderate corneal edema .</brief_summary>
	<brief_title>A Study Investigating Safety , Tolerability , Efficacy Elamipretide Topical Ophthalmic Solution Treatment Fuchs ' Corneal Endothelial Dystrophy ( FCED )</brief_title>
	<detailed_description />
	<mesh_term>Iridocorneal Endothelial Syndrome</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Adults ≥18 year old time Screening Visit Diagnosis FCED OU base clinical ophthalmic test finding Clinical evidence corneal edema OU diagnose FCED , include one follow sign : corneal epithelial microcysts , corneal epithelial bulla , stromal fold , stromal haze Central corneal thickness 550 μm 700 μm ( inclusive ) least one eye diagnose FCED , measure ultrasonic pachymetry time Screening Visit Baseline Visit Bestcorrected distance visual acuity ( BCVA ) 20/25 20/320 ( inclusive ) time Screening Visit Baseline Visit OU Women childbearing potential must agree use birth control specify protocol date sign inform consent form ( ICF ) last study Able give informed consent willing comply study visit examination Corneal finding type ( include , limited , stromal haze stromal scarring ) , either eye , , base investigator 's assessment , limit probability visual improvement corneal deturgescence Any ocular pathology require treatment topical ophthalmic drop , exception glaucoma ocular hypertension Use topical hypertonic saline drop 3 day prior Screening throughout duration study History corneal disease ( FCED ) corneal surgery either eye Current use likely need use contact lens time study History previous corneal anterior segment surgery LASIK , photorefractive keratectomy , endothelial keratoplasty , penetrate keratoplasty cataract surgery glaucoma surgery . Any disease medical condition opinion investigator would prevent subject participate study might confound study result Participation investigational drug device clinical trial within 30 day prior enrollment , plan participate investigational drug device clinical trial within 30 day study completion Women pregnant lactate Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Fuchs ' Corneal Endothelial Dystrophy</keyword>
	<keyword>FCED</keyword>
	<keyword>Ocuvia™</keyword>
	<keyword>MTP-131</keyword>
</DOC>